<--- Back
GRAIL, a healthcare company focused on early cancer detection, will begin trading on the Nasdaq under the ticker symbol “GRAL” following its spin-off from Illumina. The spin-off is set to be completed on June 24, 2024, with shares starting to trade “regular way” on June 25, 2024.
GRAIL’s primary product, the Galleri test, is a multi-cancer early detection (MCED) test that uses a simple blood draw to detect over 50 types of cancers, often before symptoms appear. This innovative approach aims to identify cancers at an earlier stage when treatment is more likely to be successful.
Illumina shareholders will receive one share of GRAIL for every six shares of Illumina they own, retaining their Illumina shares. Illumina will maintain a 14.5% stake in GRAIL. This strategic move follows regulatory challenges to Illumina’s previous acquisition of GRAIL, which was ultimately unwound.
GRAIL has already shown significant growth, reporting $93 million in revenue in 2023 and continuing to expand its clinical programs and commercial partnerships. The IPO will provide GRAIL with the financial resources needed to advance its mission of transforming cancer care through early detection technologies.
Grail has competition in an industry that is heating up. Several companies are at the forefront of developing early disease detection technologies, focusing on various innovative approaches to improve early diagnosis and treatment outcomes. Here are some notable ones:
Exact Sciences: This company is well-known for its non-invasive colorectal cancer screening test, Cologuard. Exact Sciences continues to develop other diagnostic tests for various cancers, leveraging advanced genomic technologies.
Guardant Health: Specializes in liquid biopsy technologies for cancer detection. Their Guardant360 test analyzes circulating tumor DNA in blood to detect mutations associated with different cancers, facilitating early diagnosis and treatment planning.
Illumina: The company spinning off GRAIL. While primarily known for its DNA sequencing technology, Illumina continues to support genomic research and the development of diagnostic tools.
Tempus: Uses artificial intelligence and machine learning to analyze clinical and molecular data, aiming to enhance cancer diagnosis and treatment. Tempus provides insights that help in the early detection and personalized treatment of various diseases.
Roche: This global healthcare company has made significant strides in early cancer detection technologies, including liquid biopsy platforms and advanced diagnostic solutions that help detect cancer earlier and more accurately.
Foundation Medicine: Focuses on comprehensive genomic profiling to identify the molecular alterations in a patient’s cancer, which can inform targeted treatment strategies. Their tests are used for both early detection and monitoring of cancer progression.
Biocartis: Develops and commercializes molecular diagnostic solutions aimed at improving the diagnosis of cancer and other serious diseases. Their Idylla platform allows for rapid, easy-to-use testing directly at the point of care.
Grainger Diagnostics: Specializes in AI-powered health screening and diagnostic tools that leverage advanced imaging and machine learning to detect diseases early.
These companies are leveraging advanced technologies such as liquid biopsy, next-generation sequencing, artificial intelligence, and comprehensive genomic profiling to revolutionize early disease detection, making it more accurate, accessible, and efficient.
Earlier this year our (Wall Street Whisper) parent company, Olivon Advisors and our syndicate of accredited investors invested into Cizzle Bio, Inc. the US Licensee of a UK-based diagnostics company focused on the early detection of lung cancer. Originating as a spin-out from the University of York, Cizzle PLC has developed a blood test aimed at identifying the CIZ1B biomarker, which is associated with early-stage lung cancer. This test is designed to address the high false positive rates often seen with CT scanning, providing a more reliable and less invasive method for early detection.
Cizzle Biotechnologies’ primary innovation centers around the CIZ1B biomarker, a variant of the CIZ1 protein involved in DNA replication. The presence of CIZ1B in blood plasma can indicate the early stages of lung cancer, allowing for potential curative surgical interventions. This approach promises to improve patient outcomes by enabling earlier and more accurate detection compared to current methods.
Recently, Cizzle has entered into a significant collaboration with ProteoGenix to develop new antibodies targeting the CIZ1B biomarker, further enhancing the accuracy and reliability of their diagnostic tests. This partnership aims to bring these advancements closer to clinical use and broader commercialization.
For more detailed information, you can visit their official website.